Lee Chan Henry

SVP & General Counsel Lee Chan Henry sells entire 1,660-share ONC position for $580,196.56; all 5 prior ONC sales were well-timed before declines.

Lee Chan Henry executed 2 separate sales totaling 1,660 shares for $580,196.56, completely liquidating his position in BeOne Medicines. This follows a consistent pattern: all 5 of his prior sales at this ticker were well-timed, with 90-day returns ranging from -2.8% to -8.9%, indicating the stock fell after each sale. His cross-ticker track record shows a 75.00% well-timed rate on sells, suggesting expertise in exit timing. However, the broader context presents tension: ONC shows robust fundamentals with $1.4B quarterly revenue and +55.0% annual growth, yet trades at an extreme P/E of 7078.40 and was unprofitable on a full-year basis—the recent 30-day gain of +6.0% and proximity to the 52-week high of $377.47 may explain why the SVP chose now to exit completely.

SVP/General Counsel Lee Chan Henry sells entire 10,671-share stake in ONC for $3.7M at $350.40 avg; stock now $320.10, down 8.8% from 52-week high.

Lee Chan Henry, SVP and General Counsel of BeOne Medicines Ltd., executed 4 separate sales on 2025-10-08 totaling 10,671 shares for $3,739,107.61, reducing his holdings from 10,671 shares to zero. The blended average transaction price was $350.40, and the stock currently trades at $320.10, representing an 8.8% decline from the 52-week high of $351.13. The timing is notable: Henry's prior sales at ONC on 2025-09-10 showed negative 30-day returns (-2.4%, -1.6%, -1.7%, -2.0%, -1.5%), suggesting a pattern of selling before near-term weakness, though his cross-ticker track record averaged +1.8% 30-day returns on 8 prior sells. The complete exit by a senior legal officer warrants attention, particularly given that BeOne reported annual net income was negative over its most recent full fiscal year despite $1.3B in latest quarterly revenue and 55% annual revenue growth, indicating the company is still unprofitable on a full-year basis.

Lee Chan Henry (SVP, General Counsel) divests entire 10.0K share position in ONC via 5 sales totaling $3.3M at blended avg $325.53

Lee Chan Henry executed five separate sales on 2025-09-10, liquidating his entire 10.0K share position (10,006 shares) for $3,257,288.88 at prices ranging from $325.00 to $327.93, averaging $325.53 per share. The complete exit occurred one month after his three prior sales at ONC on 2025-08-13, suggesting repeated systematic liquidation rather than a single rebalancing event. His cross-ticker track record shows 3 prior sells with an average 30-day return of +8.0%, and his three prior ONC sales on 2025-08-13 each showed positive 30-day returns (+8.1%, +8.0%, +7.8%), yet no timing data is available at the 90-day interval to assess whether prior sells preceded subsequent declines. At the current price of $324.34, the stock trades 7.6% below its 52-week high of $351.13, and while the company posted $1.3B in quarterly revenue with 55.0% annual revenue growth, it remained unprofitable over its most recent full fiscal year, creating a backdrop of strong top-line growth offset by persistent losses.

SVP General Counsel Lee Chan Henry sold all 11,013 shares (11.0K) at $300.45 blended average for $3.3M, exiting position entirely.

Lee Chan Henry, Senior Vice President and General Counsel, executed 3 separate sales totaling 11,013 shares for $3,308,877.31, liquidating his entire stake in BeOne Medicines. The sales were priced at $300.00, $300.19, and $301.00 across the filing date of 2025-08-13, versus the current price of $321.36—notably 20+ dollars above the transaction prices. BeOne Medicines is a $459.7B market cap company with strong growth (+55.0% annual revenue growth) and recent profitability ($94.3M net income in latest quarter), though the full fiscal year showed negative net income. The complete exit by a senior legal officer—particularly given the company's large revenue base and recent quarter profitability—contrasts with the stock's recent momentum (+15.1% over 30 days, +40.7% over 90 days, at 52-week highs). The absence of any continuing holdings and the full liquidation warrant examination of whether this signals executive-level confidence constraints or portfolio restructuring at the company.